RAMP shifted from profitable to unprofitable despite 13% revenue growth, driven by significantly higher R&D spending and interest costs.
The company is investing heavily in growth (17% increase in R&D) but experiencing margin compression that turned an $11.9M profit into a $814K loss. The 67% increase in share buybacks suggests management believes the stock is undervalued, though operating cash flow declined 35% which could constrain future capital allocation flexibility.
Revenue grew a solid 13% to $745.6M, but profitability deteriorated sharply as net income swung from $11.9M profit to a $814K loss due to 17% higher R&D spending and 37% increased interest expense. Operating cash flow declined 35% to $150.1M while the company accelerated share repurchases by 67% to $101.2M, indicating aggressive capital returns despite weakening cash generation. The overall picture shows a growth company prioritizing investment and shareholder returns over near-term profitability.
Net income declined 106.9% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 75.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Share repurchases increased 67.3% — management returning capital, signals confidence in intrinsic value.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Interest expense surged 37.3% — significant debt increase or rising rates materially impacting earnings.
Operating cash flow fell 34.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash grew 22.7% — improving liquidity position supports investment and shareholder returns.
R&D investment increased 16.8% — signals commitment to future product development, though near-term margin impact.
Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.
Revenue growing 13% — solid top-line momentum, watch margins for quality of growth.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →